Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SAR302503 in hydroxyurea-resistant or -intolerant polycythemia vera or essential thrombocythemia
2011-001847-58Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fedratinib in polycythemia vera (PV) and thrombocythemia (3 arms), sponsored by Sanofi. Primary endpoint: Primary endpoint (polycythemia vera). Started Jul 2011; status: completed.
02
Drugs
fedratinib
03
Conditions
polycythemia vera (PV)thrombocythemia
Beyond the preview
Go deeper on 2011-001847-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001847-58.